Krystal Biotech, Inc. Current Liabilities
Krystal Biotech, Inc. (KRYS) had Current Liabilities of $127.40 million as of 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:LiabilitiesCurrent · last filed 2026-08-03
- 2026-06-30: Liabilities, Current $127.40M.
- 2026-03-31: Liabilities, Current $107.80M.
- 2025-12-31: Liabilities, Current $102.94M.
- 2025-09-30: Liabilities, Current $91.27M.
| Period end | Liabilities, Current |
|---|---|
| 2026-06-30 | $127.40M 10-Q · filed 2026-08-03 |
| 2026-03-31 | $107.80M 10-Q · filed 2026-05-04 |
| 2025-12-31 | $102.94M 10-Q · filed 2026-08-03 |
| 2025-09-30 | $91.27M 10-Q · filed 2025-11-03 |
| 2025-06-30 | $86.90M 10-Q · filed 2025-08-04 |
| 2025-03-31 | $79.49M 10-Q · filed 2025-05-06 |
| 2024-12-31 | $102.00M 10-K · filed 2026-02-17 |
| 2024-09-30 | $89.53M 10-Q · filed 2024-11-04 |
| 2024-06-30 | $71.85M 10-Q · filed 2024-08-05 |
| 2024-03-31 | $47.59M 10-Q · filed 2024-05-06 |
| 2023-12-31 | $33.09M 10-K · filed 2025-02-19 |
| 2023-09-30 | $27.58M 10-Q · filed 2023-11-06 |
| 2023-06-30 | $23.90M 10-Q · filed 2023-08-07 |
| 2023-03-31 | $35.08M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $28.85M 10-K · filed 2024-02-26 |
| 2022-09-30 | $28.03M 10-Q · filed 2022-11-07 |
| 2022-06-30 | $34.43M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $60.44M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $25.74M 10-K · filed 2023-02-27 |
| 2021-09-30 | $35.78M 10-Q · filed 2021-11-08 |
| 2021-06-30 | $18.12M 10-Q · filed 2021-08-09 |
| 2021-03-31 | $9.14M 10-Q · filed 2021-05-10 |
| 2020-12-31 | $15.45M 10-K · filed 2022-02-28 |
| 2020-09-30 | $7.20M 10-Q · filed 2020-11-09 |
| 2020-06-30 | $5.83M 10-Q · filed 2020-08-07 |
| 2020-03-31 | $4.06M 10-Q · filed 2020-05-04 |
| 2019-12-31 | $3.33M 10-K · filed 2021-03-01 |
| 2019-09-30 | $3.73M 10-Q · filed 2019-11-04 |
| 2019-06-30 | $3.94M 10-Q · filed 2019-08-05 |
| 2019-03-31 | $3.24M 10-Q · filed 2019-05-07 |
| 2018-12-31 | $2.60M 10-K · filed 2020-03-10 |
| 2018-09-30 | $1.92M 10-Q · filed 2018-11-05 |
| 2018-06-30 | $759.00K 10-Q · filed 2018-08-06 |
| 2018-03-31 | $452.00K 10-Q · filed 2018-05-07 |
| 2017-12-31 | $640.00K 10-Q · filed 2018-11-05 |
| 2017-09-30 | $2.48M 10-Q · filed 2017-11-13 |
| 2016-12-31 | $43.00K 10-K · filed 2018-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |